<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">AMPICILLIN SODIUM AND SULBACTAM SODIUM</span><br/>(am-pi-sill'in/sul-bak'tam)<br/><span class="topboxtradename">Unasyn<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">antibiotic</span>; <span class="classification">aminopenicillin</span><br/><b>Prototype: </b>Ampicillin<br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>1.5 gm, 3 gm vials</p>
<h1><a name="action">Actions</a></h1>
<p>Antibiotic agent with activity resulting from beta-lactamase inhibition. Sulbactam inhibits beta-lactamases most frequently
         responsible for transferred drug resistance. Because of this action, a wide range of beta-lactamases found in organisms resistant
         to penicillins and cephalosporins have their growth inhibited.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Effective against both gram-positive and gram-negative bacteria including those that produce beta-lactamase and nonbeta-lactamase
         producers. Ampicillin without sulbactam is not effective against beta-lactamase producing strains.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of infections due to susceptible organisms in skin and skin structures, intraabdominal infections, and gynecologic
         infections.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to penicillins; mononucleosis.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Hypersensitivity to cephalosporins; pregnancy (category B) or lactation.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Systemic Infections</span><br/><span class="rdage">Adult/</span><span class="rdage">Child:</span> <span class="rdroute">IV/IM</span> <img src="../images/special/greaterorequal.gif"/><i>40 kg</i>, 1.5 (1 g ampicillin, 0.5 g sulbactam) to 3 g (2 g ampicillin, 1 g sulbactam) q6h (max: 4 g sulbactam/d)<br/><span class="rdage">Child:</span> <span class="rdroute">IV</span> <img src="../images/special/greaterorequal.gif"/><i>1 y</i>, 300 mg/kg/d (200 mg/kg ampicillin and 100 mg/kg sulbactam) divided q6h<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Intramuscular</span><br/><ul>
<li>Reconstitute solution with sterile water for injection by adding 6.4 mL diluent to a 3 g vial. Each mL contains 250 mg ampicillin
            and 125 mg sulbactam.
         </li>
<li>Give deep IM into a large muscle. Rotate injection sites.</li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct/</span><span class="methodtype">Intermittent:</span> Reconstitute each 1.5 g with 3.2 mL of sterile water for injection to yield 375 mg/mL (250 mg ampicillin/125 mg sulbactam);
                  further dilute with NS, D5W, D5/NS, D5W/0.45NS, or RL to a final concentration within the range of 345 mg/mL.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Direct/</span><span class="methodtype">Intermittent :</span> Give slowly over at least 15 min.  With solutions of 100 mL or more, set rate according to amount of solution but no faster than direct IV rate.  Convulsions may be induced by too rapid administration.  Use only freshly prepared solution; administer within 1 h after preparation. 
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype"> Solution/additive:</span> Do not add to a <b>dextrose-</b>containing solution unless entire dose is given within 1 h of preparation. <span class="incompattype">Y-site:</span> <b>Amiodarone.</b>
</p>
</td>
</tr>
</table>
<ul>
<li>Store powder for injection at 15°30° C (59°86° F) before reconstitution. Storage times and
            temperatures vary for different concentrations of reconstituted solutions; consult manufacturer's directions.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Hypersensitivity (rash, itching, <span class="speceff-life">anaphylactoid reaction</span>), fatigue, malaise, headache, chills, edema. <span class="typehead">GI:</span>
<span class="speceff-common">Diarrhea, nausea,</span> vomiting, abdominal distention, candidiasis. <span class="typehead">Hematologic:</span> Neutropenia, thrombocytopenia. <span class="typehead">Urogenital:</span> Dysuria. <span class="typehead">CNS:</span> Seizures. <span class="typehead">Other:</span> Local pain at injection site; thrombophlebitis. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Allopurinol</b> increases incidence of rash; effectiveness of the <span class="classification">aminoglycosides</span> may be impaired in patients with severe end stage renal disease; <b>chloramphenicol,</b>
<b>erythromycin,</b>
<b>tetracycline</b> may reduce bactericidal effects of ampicillinthis interaction is primarily significant when low doses are used; ampicillin
      may interfere with the contraceptive action of <span class="classification">oral contraceptives</span>female patients should be advised to consider nonhormonal contraception while on antibiotics. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Peak:</span> Immediate after IV. <span class="typehead"> Duration:</span>  68 h. <span class="typehead">Distribution:</span> Most body tissues; high CNS concentrations only with inflamed meninges; crosses placenta; appears in breast milk. <span class="typehead">Metabolism:</span> Minimal hepatic metabolism. <span class="typehead">Elimination:</span> Excreted in urine. <span class="typehead">Half-Life:</span> 1 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Determine previous hypersensitivity reactions to penicillins, cephalosporins, and other allergens prior to therapy.</li>
<li>Lab tests: Baseline C&amp;S tests prior to initiation of therapy; start drug pending results.</li>
<li>Report promptly unexplained bleeding (e.g., epistaxis, purpura, ecchymoses).</li>
<li>Monitor patient carefully during the first 30 min after initiation of IV therapy for signs of hypersensitivity and anaphylactoid
            reaction (see Appendix F). Serious anaphylactoid reactions require immediate use of emergency drugs and airway management.
         </li>
<li>Observe for and report symptoms of superinfections (see Appendix F). Withhold drug and notify physician.</li>
<li>Monitor I&amp;O ratio and pattern. Report dysuria, urine retention, and hematuria.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report chills, wheezing, pruritus (itching), respiratory distress, or palpitations to physician immediately.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>